Identification
- Summary
Inositol is an ingredient found in a variety of nutritional products.
- Brand Names
- Alertonic
- Generic Name
- Inositol
- DrugBank Accession Number
- DB13178
- Background
Inositol is a collection of nine different stereoisomers but the name is usually used to describe only the most common type of inositol, myo-inositol. Myo-inositol is the cis-1,2,3,5-trans-4,6-cyclohexanehexol and it is prepared from an aqueous extract of corn kernels by precipitation and hydrolysis of crude phytate. These molecules have structural similarities to glucose and are involved in cellular signaling. It is considered a pseudovitamin as it is a molecule that does not qualify to be an essential vitamin because even though its presence is vital in the body, a deficiency in this molecule does not translate into disease conditions.26 Inositol can be found as an ingredient of OTC products by Health Canada but all current product whose main ingredient is inositol are discontinued.27 By the FDA, inositol is considered in the list of specific substances affirmed as generally recognized as safe (GRAS).28
- Type
- Small Molecule
- Groups
- Approved, Investigational, Withdrawn
- Structure
Structure for Inositol (DB13178)
- Weight
- Average: 180.1559
Monoisotopic: 180.063388116 - Chemical Formula
- C6H12O6
- Synonyms
- 1,2,3,5/4,6-cyclohexanehexol
- cis-1,2,3,5-trans-4,6-cyclohexanehexol
- Inositol
- L-myo-Inositol
- Meat sugar
- meso-Inositol
- myo-inositol
- External IDs
- NSC-8101
Pharmacology
- Indication
Inositol may be used in food without any limitation. As a drug, inositol is used as a nutrient supplement in special dietary foods and infant formula.28 As it presents a relevant role in ensuring oocyte fertility, inositol has been studied for its use in the management of polycystic ovaries.1 Inositol is also being researched for the treatment of diabetes,2 prevention of metabolic syndrome,4 aid agent for weight loss,5 treatment of depression, psychiatric disorder and anxiety disorder6 and for prevention of cancer.7
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Inositol can stimulate glucose uptake in skeletal muscle cells which allows the decrease in blood sugar levels. This effect is later seen as a reduction in urine glucose concentration and indicates a decrease in high blood sugar levels.8
In PCOS, the administration of inositol has produced the remission of symptoms as well as a reduction in male hormone secretion9, a regulation of the cholesterol level,4 and a more efficient fat breakdown which allow to a significant reduction on body mass and appetite.10
In the cases of infertility, inositol has been proven to increase sperm count and motility,14 as well as increase the overall quality of oocytes and embryos.15
In the brain, inositol has been shown to produce an increase in serotonin receptor sensitivity. This activity produces an increase in GABA release.11 Some of the effects observed in the brain produced a relief in symptoms of anxiety and obsessive-compulsive disorders.12 In high doses, it has been shown to even reduce panic attacks.13
In cancer research, inositol has gained interest as it can act as an antioxidant, anti-inflammatory and it seems to enhance immune properties.7
- Mechanism of action
The mechanism of action of inositol in brain disorders is not fully understood but it is thought that it may be involved in neurotransmitter synthesis and it is a precursor to the phosphatidylinositol cycle. The change that occurs in the cycle simulates when the postsynaptic receptor is activated but without activating the receptor. This activity provokes a fake activation which regulated the activity of monoamines and other neurotransmitters.25
Reports have shown that insulin resistance plays a key role in the clinical development of PCOS. The presence of hyperinsulinemia can induce an excess in androgen production by stimulating ovaries to produce androgens and by reducing the sex hormone binding globulin serum levels. One of the mechanisms of insulin deficiency is thought to be related to a deficiency in inositol in the inositolphosphoglycans. The administration of inositol allows it to act as a direct messenger of the insulin signaling and improves glucose tissue uptake.16 This mechanism is extrapolated to its functions in diabetes treatment, metabolic syndrome, and weight loss.29
In cancer, the mechanism of action of inositol is not fully understood. It is hypothesized that the administration of inositol increases the level of lower-phosphate inositol phosphates why can affect cycle regulation, growth, and differentiation of malignant cells. On the other hand, the formation of inositol hexaphosphate after administration of inositol presents antioxidant characteristics by the chelation of ferric ions and suppression of hydroxyl radicals.17
- Absorption
Inositol is absorbed from the small intestine.25 In patients with inositol deficiency, the maximal plasma concentration after oral administration of inositol is registered to be of 4 hours.19 Inositol is taken up by the tissues via sodium-dependent inositol co-transporter which also mediates glucose uptake.20 Oral ingestion of inositol is registered to generate a maximal plasma concentration of 36-45 mcg.21
- Volume of distribution
The pharmacokinetic profile of inositol was studied in preterm infants and the estimated volume of distribution was reported to be 0.5115 L/kg.18
- Protein binding
It is thought that inositol can be found bound to plasma proteins.
- Metabolism
It is thought that inositol is metabolized to phosphoinositol and then converted to phosphatylinositol-4,5-biphosphate which is a precursor of the second-messenger molecules.25 Inositol can be transformed to D-chiro-inositol via the actions of an epimerase. The normal modifications to inositol structure seem to be between all the different isomers.22
Hover over products below to view reaction partners
- Route of elimination
Most of the administered dose is excreted in urine.23
- Half-life
The pharmacokinetic profile of inositol was studied in preterm infants and the estimated elimination half-life was reported to be of 5.22 hours.18
- Clearance
The pharmacokinetic profile of inositol was studied in preterm infants and the estimated clearance rate was reported to be 0.0679 L.kg/h.18
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Consumption of high doses of inositol is reported to only cause some gastrointestinal effects.24
- Pathways
Pathway Category Inositol Metabolism Metabolic Galactose Metabolism Metabolic Galactosemia Disease Joubert Syndrome Disease Inositol Phosphate Metabolism Metabolic Phosphatidylinositol Phosphate Metabolism Metabolic - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Inositol which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Inositol which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Inositol which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Inositol which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Inositol 250mg - Tab Tablet 250 mg Oral International Nutrition Ltd. 1996-07-26 2001-08-17 Canada 
Inositol 500mg Tablet 500 mg Oral Great Earth Companies, Inc. 1998-08-25 2002-10-02 Canada Inositol Caps 500mg Capsule 500 mg / cap Oral Twin Laboratories Inc. 1995-12-31 1999-11-10 Canada Inositol Ctr Srt 400mg Tablet, extended release 400 mg / tab Oral Bioenergy Inc. 1979-12-31 1998-06-03 Canada Inositol Tab 250mg Tablet 250 mg / tab Oral Les Laboratoires Bio SantÉ Inc. 1985-12-31 1996-09-10 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 24 Multivitamins + Minerals Inositol (25 mg) + Ascorbic acid (150 mg) + Beta carotene (10000 unit) + Biotin (25 mcg) + Calcium (130 mg) + Cholecalciferol (400 unit) + Choline bitartrate (25 mg) + Chromium (20 mcg) + Copper (1 mg) + Cyanocobalamin (25 mcg) + Ferrous fumarate (15 mg) + Folic acid (.8 mg) + Magnesium (65 mg) + Manganese (2 mg) + Molybdenum (20 mcg) + Niacin (25 mg) + Calcium pantothenate (25 mg) + Potassium (15 mg) + Potassium Iodide (.1 mg) + Pyridoxine hydrochloride (25 mg) + Racemethionine (25 mg) + Riboflavin (25 mg) + Selenium (20 mcg) + Thiamine hydrochloride (25 mg) + Vanadium (20 mcg) + Vitamin A palmitate (5000 unit) + Vitamin E (50 unit) + Zinc (10 mg) Tablet Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1997-04-30 2002-07-31 Canada 50 Plus Inositol (20 mg) + Ascorbic acid (200 mg) + Biotin (20 mcg) + Choline bitartrate (20 mg) + Cyanocobalamin (20 mcg) + Folic acid (.2 mg) + Niacin (20 mg) + Calcium pantothenate (20 mg) + Pyridoxine hydrochloride (20 mg) + Racemethionine (20 mg) + Riboflavin (20 mg) + Thiamine hydrochloride (20 mg) + Vitamin A palmitate (10000 unit) + Vitamin D (400 unit) + Vitamin E (20 unit) Tablet Oral Quest Vitamins A Div Of Purity Life Health Products 1998-08-04 2001-07-06 Canada Advanced 2000 Capsules Inositol (15 mg) + Choline (15 mg) + Chromium (50 mcg) + Manganese (1 mg) + Pantothenic acid (15 mg) + Pyridoxine hydrochloride (4 mg) Capsule Oral Body Gold, A Division Of Pep Products, Inc. 2000-01-01 2002-08-22 Canada Alertonic Inositol (2.222 mg / mL) + Choline (2.222 mg / mL) + Nicotinamide (1.111 mg / mL) + Pipradrol hydrochloride (0.044 mg / mL) + Pyridoxine hydrochloride (0.042 mg / mL) + Riboflavin (0.111 mg / mL) + Thiamine hydrochloride (0.222 mg / mL) Elixir Oral Odan Laboratories Ltd 1995-12-31 Not applicable Canada Alertonic Inositol (2.222 mg / mL) + Choline (2.222 mg / mL) + Nicotinamide (1.111 mg / mL) + Pipradrol hydrochloride (.044 mg / mL) + Pyridoxine hydrochloride (.042 mg / mL) + Riboflavin (.111 mg / mL) + Thiamine hydrochloride (.222 mg / mL) Liquid Oral Merrell Pharms Inc., Division Of Merrell Dow (Can) 1967-12-31 1996-09-09 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Lipovite Inositol (1 mg/1mL) + Choline (1 mg/1mL) + Chromium (1 mg/1mL) + Citrulline (1 mg/1mL) + Dexpanthenol (1 mg/1mL) + Levocarnitine (1 mg/1mL) + Lidocaine (1 mg/1mL) + Mecobalamin (1 mg/1mL) + Methionine sulfoximine (1 mg/1mL) + Nicotinamide (1 mg/1mL) + Pyridoxine (1 mg/1mL) + Riboflavin (1 mg/1mL) + Thiamine chloride (1 mg/1mL) Injection Intramuscular Perdido Key Health And Wellness Inc 2015-11-23 Not applicable US 
Mic B12 Inositol (1 mg/1mL) + Choline C-11 (1 mg/1mL) + Mecobalamin (1 mg/1mL) + Methionine sulfoximine (1 mg/1mL) Injection Intramuscular Perdido Key Health And Wellness Inc 2015-11-23 Not applicable US Neonatal Plus Vitamin Inositol (5 mg/1) + Ascorbic acid (20 mg/1) + Boron (0.2 mg/1) + Calcium (200 mg/1) + Cholecalciferol (10 ug/1) + Citrus bioflavonoids (2 mg/1) + Copper (2 mg/1) + Cyanocobalamin (12 ug/1) + Ferrous fumarate (27 mg/1) + Folic acid (1000 ug/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (10 mg/1) + Riboflavin (3 mg/1) + Thiamine chloride (1.84 mg/1) + Vitamin A (1200 ug/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (9.2 mg/1) Tablet Oral Neomed Pharmaceutical 2018-07-31 Not applicable US
Categories
- ATC Codes
- A11HA07 — Inositol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cyclohexanols. These are compounds containing an alcohol group attached to a cyclohexane ring.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Alcohols and polyols
- Direct Parent
- Cyclohexanols
- Alternative Parents
- Sugar alcohols / Cyclitols and derivatives / Polyols / Hydrocarbon derivatives
- Substituents
- Aliphatic homomonocyclic compound / Cyclic alcohol / Cyclitol or derivatives / Cyclohexanol / Hydrocarbon derivative / Polyol / Sugar alcohol
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- inositol (CHEBI:17268)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 4L6452S749
- CAS number
- 87-89-8
- InChI Key
- CDAISMWEOUEBRE-GPIVLXJGSA-N
- InChI
- InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-
- IUPAC Name
- (1R,2R,3r,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol
- SMILES
- O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O
References
- General References
- Bizzarri M, Carlomagno G: Inositol: history of an effective therapy for Polycystic Ovary Syndrome. Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1896-903. [Article]
- Werner EF, Froehlich RJ: The Potential Role for Myoinositol in the Prevention of Gestational Diabetes Mellitus. Am J Perinatol. 2016 Nov;33(13):1236-1241. doi: 10.1055/s-0036-1584273. Epub 2016 May 23. [Article]
- Sam S: Obesity and Polycystic Ovary Syndrome. Obes Manag. 2007 Apr;3(2):69-73. doi: 10.1089/obe.2007.0019. [Article]
- Gerli S, Papaleo E, Ferrari A, Di Renzo GC: Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347-54. [Article]
- Andersen DB, Holub BJ: The relative response of hepatic lipids in the rat to graded levels of dietary myo-inositol and other lipotropes. J Nutr. 1980 Mar;110(3):496-504. doi: 10.1093/jn/110.3.496. [Article]
- Rango M, Cogiamanian F, Marceglia S, Barberis B, Arighi A, Biondetti P, Priori A: Myoinositol content in the human brain is modified by transcranial direct current stimulation in a matter of minutes: a 1H-MRS study. Magn Reson Med. 2008 Oct;60(4):782-9. doi: 10.1002/mrm.21709. [Article]
- Han W, Gills JJ, Memmott RM, Lam S, Dennis PA: The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila). 2009 Apr;2(4):370-6. doi: 10.1158/1940-6207.CAPR-08-0209. Epub 2009 Mar 31. [Article]
- Ortmeyer HK: Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys. Obes Res. 1996 Nov;4(6):569-75. [Article]
- Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A: Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009 Aug;25(8):508-13. doi: 10.1080/09513590903015544. [Article]
- Gerli S, Mignosa M, Di Renzo GC: Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151-9. [Article]
- Ciranna L: Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol. 2006 Apr;4(2):101-14. [Article]
- Palatnik A, Frolov K, Fux M, Benjamin J: Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001 Jun;21(3):335-9. [Article]
- Levine J: Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997 May;7(2):147-55. [Article]
- Condorelli RA, La Vignera S, Bellanca S, Vicari E, Calogero AE: Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology. 2012 Jun;79(6):1290-5. doi: 10.1016/j.urology.2012.03.005. [Article]
- Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP: Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014 Jul;21(7):854-858. doi: 10.1177/1933719113518985. Epub 2014 Feb 4. [Article]
- Regidor PA, Schindler AE: Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study. Int J Endocrinol. 2016;2016:9537632. doi: 10.1155/2016/9537632. Epub 2016 Aug 23. [Article]
- Vucenik I, Shamsuddin AM: Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr. 2003 Nov;133(11 Suppl 1):3778S-3784S. [Article]
- Phelps DL, Ward RM, Williams RL, Nolen TL, Watterberg KL, Oh W, Goedecke M, Ehrenkranz RA, Fennell T, Poindexter BB, Cotten CM, Hallman M, Frantz ID 3rd, Faix RG, Zaterka-Baxter KM, Das A, Ball MB, Lacy CB, Walsh MC, Carlo WA, Sanchez PJ, Bell EF, Shankaran S, Carlton DP, Chess PR, Higgins RD: Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res. 2016 Aug;80(2):209-17. doi: 10.1038/pr.2016.97. Epub 2016 Apr 13. [Article]
- Grases F, Simonet BM, Vucenik I, Prieto RM, Costa-Bauza A, March JG, Shamsuddin AM: Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans. Biofactors. 2001;15(1):53-61. [Article]
- Coady MJ, Wallendorff B, Gagnon DG, Lapointe JY: Identification of a novel Na+/myo-inositol cotransporter. J Biol Chem. 2002 Sep 20;277(38):35219-24. doi: 10.1074/jbc.M204321200. Epub 2002 Jul 19. [Article]
- Carlomagno G, De Grazia S, Unfer V, Manna F: Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012 Mar;9(3):267-71. doi: 10.1517/17425247.2012.662953. [Article]
- Yamashita Y, Yamaoka M, Hasunuma T, Ashida H, Yoshida K: Detection of orally administered inositol stereoisomers in mouse blood plasma and their effects on translocation of glucose transporter 4 in skeletal muscle cells. J Agric Food Chem. 2013 May 22;61(20):4850-4. doi: 10.1021/jf305322t. Epub 2013 May 13. [Article]
- DAUGHADAY WH, LARNER J: The renal excretion of inositol in normal and diabetic human beings. J Clin Invest. 1954 Mar;33(3):326-32. doi: 10.1172/JCI102901. [Article]
- Carlomagno G, Unfer V: Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6. [Article]
- Kapalka G. (2010). Practical resources for the Mental Health Professional. Academic Press.
- Examine [Link]
- Health Canada [Link]
- FDA code of federal regulations [Link]
- Inositol report University of Wisconsin [File]
- External Links
- Human Metabolome Database
- HMDB0000211
- KEGG Drug
- D08079
- KEGG Compound
- C00137
- PubChem Substance
- 347829280
- ChemSpider
- 10239179
- 5833
- ChEBI
- 17268
- ChEMBL
- CHEMBL1222251
- ZINC
- ZINC000100018867
- PDBe Ligand
- INS
- Wikipedia
- Inositol
- PDB Entries
- 1aod / 1g0i / 1iev / 1ptg / 1y7v / 2huo / 2os9 / 2r71 / 2x1i / 3bxd … show 28 more
- MSDS
- Download (53.1 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Not Available Polycystic Ovarian Syndrome (PCOS) 1 4 Completed Treatment Diabetic Peripheral Neuropathic Pain (DPN) 1 4 Completed Treatment Fatigue 1 4 Completed Treatment Pediatric Bipolar Spectrum Disorders 1 4 Recruiting Treatment Alternative Treatment / Mood Disturbances / Moods Disorders / Natural Supplements 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Elixir Oral Liquid Oral Cream Vaginal Tablet, film coated Oral Solution Oral Powder Oral Tablet, film coated Tablet, extended release Oral Tablet Oral 250 mg Tablet Oral 500 mg Capsule Oral 500 mg / cap Tablet, extended release Oral 400 mg / tab Tablet Oral 250 mg / tab Tablet Oral 405 mg / tab Tablet Oral 400 mg Injection Intramuscular Kit Oral Capsule Oral Tablet Oral Liquid; tablet Oral Powder, for solution Oral Capsule, gelatin coated Oral Tablet, sugar coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 224.5 ºC 'MSDS' boiling point (°C) 291.33 ºC 'MSDS' water solubility 0.17 mg/ml United States Pharmacopeial Convention. logP -2.08 'MSDS' - Predicted Properties
Property Value Source Water Solubility 485.0 mg/mL ALOGPS logP -2.6 ALOGPS logP -3.8 Chemaxon logS 0.43 ALOGPS pKa (Strongest Acidic) 12.29 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 121.38 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 35.78 m3·mol-1 Chemaxon Polarizability 16.14 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 136.8079761 predictedDarkChem Lite v0.1.0 [M-H]- 137.0430761 predictedDarkChem Lite v0.1.0 [M-H]- 136.7352761 predictedDarkChem Lite v0.1.0 [M-H]- 141.73029 predictedDeepCCS 1.0 (2019) [M-H]- 136.8079761 predictedDarkChem Lite v0.1.0 [M-H]- 137.0430761 predictedDarkChem Lite v0.1.0 [M-H]- 136.7352761 predictedDarkChem Lite v0.1.0 [M-H]- 141.73029 predictedDeepCCS 1.0 (2019) [M+H]+ 138.0892761 predictedDarkChem Lite v0.1.0 [M+H]+ 137.5356761 predictedDarkChem Lite v0.1.0 [M+H]+ 140.5961761 predictedDarkChem Lite v0.1.0 [M+H]+ 144.12584 predictedDeepCCS 1.0 (2019) [M+H]+ 138.0892761 predictedDarkChem Lite v0.1.0 [M+H]+ 137.5356761 predictedDarkChem Lite v0.1.0 [M+H]+ 140.5961761 predictedDarkChem Lite v0.1.0 [M+H]+ 144.12584 predictedDeepCCS 1.0 (2019) [M+Na]+ 136.6261761 predictedDarkChem Lite v0.1.0 [M+Na]+ 142.592911 predictedDarkChem Standard v0.1.0 [M+Na]+ 136.4495761 predictedDarkChem Lite v0.1.0 [M+Na]+ 150.69893 predictedDeepCCS 1.0 (2019) [M+Na]+ 136.6261761 predictedDarkChem Lite v0.1.0 [M+Na]+ 142.592911 predictedDarkChem Standard v0.1.0 [M+Na]+ 136.4495761 predictedDarkChem Lite v0.1.0 [M+Na]+ 150.69893 predictedDeepCCS 1.0 (2019)
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Prevents intracellular accumulation of high concentrations of myo-inositol (an osmolyte) that result in impairment of cellular function.
- Specific Function
- Myo-inositol
- Gene Name
- SLC5A3
- Uniprot ID
- P53794
- Uniprot Name
- Sodium/myo-inositol cotransporter
- Molecular Weight
- 79693.065 Da
References
- Coady MJ, Wallendorff B, Gagnon DG, Lapointe JY: Identification of a novel Na+/myo-inositol cotransporter. J Biol Chem. 2002 Sep 20;277(38):35219-24. doi: 10.1074/jbc.M204321200. Epub 2002 Jul 19. [Article]
Drug created at June 06, 2017 20:13 / Updated at February 20, 2024 23:55